Synthesis, characterization and antitumor activity study of some cyclometalated organoplatinum(II) complexes containing aromatic N-donor ligands

A general approach has been designed to synthesize some mononuclear and binuclear cyclometalated platinum(II) complexes, containing aromatic N-donor ligands with the presence of one Cl−trans to carbon. In this way, cyclometalated platinum(II) complex [Pt(C^N)Cl(dmso)], 1, C^N = N(1),C(2′)-chelated, deprotonated 2-phenylpyridine and dmso = dimethylsulfoxide, was used as a precursor to react with imidazole derivatives (1-methylimidazole, 2a, imidazole, 2b,), monodentate pyridine derivatives (4-methylpyridine, 2c, pyridine, 2d,) and bidentate pyridine derivative (4,4′-bipyridine, 3 and 4,). Synthesized complexes were fully characterized by using multinuclear NMR spectroscopy (1H, 13C{1H} and 195Pt), correlation NMR spectroscopy (1H-1H COSY, 13C{1H}-1H Heteronuclear Multiple Quantum Correlation, HMQC, Heteronuclear Multiple Bond Correlation, HMBC, 15N-1H HETCOR), elemental analysis, X-ray crystallography and ESI-Mass spectrometry. Antitumor effects of mononuclear cyclometalated platinum(II) complexes 2a, 2c, 2d and 3 were determined on Jurkat, K562, and Raji cell lines and results showed reasonable cytotoxicities.

Synthesis of some prodrug cyclometalated platinum(II) complexes, containing aromatic N-donor ligands with the presence of one Cl trans to carbon are reported. These complexes were well characterized by using multinuclear NMR spectroscopy, X-ray crystallography and ESI-Mass spectrometry.Figure optionsDownload as PowerPoint slideHighlights
► A method for synthesizing prodrugs of organoplatinum(II) complexes were reported.
► Full solution and solid state structural details of new complexes were checked.
► The complexes showed reasonable antitumor activities in human cell lines.